CIK 0001533040 · Non-accelerated filer<br>Smaller reporting company
Phio Pharmaceuticals Corp.
Sign in to watch- Ticker
- PHIO
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 453215903
- Phone
- (508) 767-3861
- Business address
- 411 SWEDELAND ROAD, SUITE 23-1080, KING OF PRUSSIA, PA, 19406
- Former names
- RXi Pharmaceuticals Corp
- 4 Grant or award President & CEO acquired 80,000 shares (grant or award)
- 4 Grant or award Director acquired 37,500 shares (grant or award)
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Open-market buy President & CEO bought 5,000 shares at $0.72 ($3,596)
- 4 Open-market buy President & CEO bought 4,000 shares at $1.17 ($4,680)
- 4 Open-market buy President & CEO bought 2,000 shares at an average $1.24 ($2,487)
- 4 Open-market buy Director bought 5,000 shares at an average $1.20 ($5,981)
- 4 Open-market buy President & CEO bought 10,000 shares at $1.03 ($10,300)
- 4 Open-market buy President & CEO bought 2,500 shares at an average $1.59 ($3,968)
- 4 Open-market buy President & CEO bought 3,000 shares at $1.68 ($5,040)
- 4 Open-market buy President & CEO bought 4,500 shares at $2.20 ($9,900)
- 4 Open-market buy President & CEO bought 5,000 shares at $2.08 ($10,390)
- 4 Open-market buy President & CEO bought 10,000 shares at an average $2.18 ($21,849)
- 4 Open-market buy No longer 10% owner bought 400 shares at $2.48 ($992)
Page 10 of 15 · 281 filings